Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...
Cantor initiated Amgen (NASDAQ:AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback